taxus/infarction

Linkul este salvat în clipboard

Alegeți tipul de sortare

Pagină 1 din 23 rezultate

Comparison of Cypher Select and Taxus Express Coronary Stents

Numai utilizatorii înregistrați pot traduce articole

Design: - Randomized open multicentre trial. Patients: - 1800 patients with coronary artery disease scheduled for percutaneous coronary intervention with stent implantation. Inclusion criteria: - Patients with coronary artery disease scheduled for percutaneous coronary intervention with stent

Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP

Numai utilizatorii înregistrați pot traduce articole

Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

Numai utilizatorii înregistrați pot traduce articole

It was reported that low-dose angiotensin II receptor blocker, candesartan, was effective to prevent cardiovascular events in patients with coronary artery disease treated with coronary angioplasty (Am Heart J 146:E20, 2003). In this study, patients without significant coronary stenosis on follow-up

Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics

Numai utilizatorii înregistrați pot traduce articole

Primary Endpoint: Composite safety endpoint of Target Vessel Failure (TVF) rate at 12 months post-index procedure: - Cardiac Death related to target vessel - Target Vessel Myocardial Infarction (TV-MI) - Target Vessel Revascularization (TVR) Secondary Endpoint: Clinical endpoints measured at 30, 180

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

Numai utilizatorii înregistrați pot traduce articole

Previous studies have documented that a slow-release polymeric sirolimus-eluting stent (Cypher, Cordis) and paclitaxel-eluting stent (Taxus, Boston Scientific) reduce neointimal formation and result in decrease of angiographic restenosis and target lesion revascularization at 1-3 years in the

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Numai utilizatorii înregistrați pot traduce articole

Prospective, 2 x 2 factorial single blind, randomized, multi-center trial of 3400 patients enrolled at up to 200 centers. Patients will be randomized 1:1 in the emergency room to a) anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition vs. b) bivalirudin and bail-out GP

Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction

Numai utilizatorii înregistrați pot traduce articole

Previous randomized trials have shown the efficacy of a slow-release polymeric sirolimus-eluting stent (CYPHER, Cordis, Warren, NJ, USA), paclitaxel-eluting stent (TAXUS, Boston Scientific, Natick, MA, USA), and zotarolimus-eluting stent (Endeavor, Medtronic, Minneapolis, MN, USA) over bare metal

Trimethylamine N-oxide in Myocardial Infarction

Numai utilizatorii înregistrați pot traduce articole

This study includes patients with their first STEMI. The investigators measure plasma TMAO levels using the frozen plasma at the onset of STEMI and 10 months later (the chronic phase). To assess plaque progression, residual SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and

OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA

Numai utilizatorii înregistrați pot traduce articole

A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial

Numai utilizatorii înregistrați pot traduce articole

PITT PCI Xience Registry

Numai utilizatorii înregistrați pot traduce articole

The introduction of drug-eluting stents (DES) into clinical practice is universally regarded as a revolutionary breakthrough in reducing the incidence of restenosis following percutaneous coronary intervention (PCI). The coating of stents with antiproliferative properties addresses a fundamental

Retrospective Study of the Impact of Drug Eluting Stents

Numai utilizatorii înregistrați pot traduce articole

A major limitation of percutaneous coronary stenting compared to coronary artery bypass grafting surgery has been the significantly higher need for repeat revascularization due to restenosis occurring at or near the stent site. By eluting a potent anti-proliferative agent from a polymer coated stent

Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions

Numai utilizatorii înregistrați pot traduce articole

Research Question: What is the effect of the paclitaxel eluting TAXUS® Liberté® stent compared with the bare-metal Liberté® stent (both Boston Scientific Corporation, Natick, MA) in saphenous vein graft (SVG) percutaneous coronary interventions (PCI) when used in conjunction with a glycoprotein

Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World

Numai utilizatorii înregistrați pot traduce articole

The use of stents has become common practice in the percutaneous treatment of coronary artery disease. Restenosis affected 20-40% of de novo coronary lesions treated with bare metal stents. Drug-eluting stents (DES) have emerged as the most effective strategy for the prevention of restenosis. The

Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents

Numai utilizatorii înregistrați pot traduce articole

This is a prospective, multicenter, randomized study assessing the efficacy of stenting moderate SVG lesions (30% to 60% by visual estimation) with paclitaxel-eluting stents in the prevention of SVG atherosclerosis progression and cardiac events at follow-up. Patients with previous coronary bypass

Anterior
1
2
Următor →

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate